Co-Diagnostics, Inc. Announces Third Quarter 2024 Earnings Release Date and Webcast

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Co-Diagnostics (NASDAQ: CODX) announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. ET the same day, featuring CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson. The event will be accessible via webcast on the company's investor relations website and through conference call lines. A recording will be available later on the company's website for those unable to attend live.

News Market Reaction

+1.63%

1 alert

+1.63% News Effect

On the day this news was published, CODX gained 1.63%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

10/25/2024 - 04:01 PM

SALT LAKE CITY, Oct. 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2024 results on Thursday, November 7, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts and institutional investors. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.

The conference call and webcast will be available via:

Webcast: ir.codiagnostics.com on the Events & Webcasts page

Conference Call: 844-481-2661 (domestic) or 412-317-0652 (international)

If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website.

About Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to locate genetic markers for use in applications other than infectious disease.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-announces-third-quarter-2024-earnings-release-date-and-webcast-302287677.html